Steve Bryson, PhD, science writer —

The U.S. Food and Drug Administration (FDA) has given NovelMed the green light to initiate a Phase 2 clinical trial to test its investigational antibody-based therapy ruxoprubart in adults with ANCA-associated vasculitis (AAV). The Phase 2 study (NCT06226662) will evaluate the therapy’s safety and efficacy in up…

High blood creatinine levels and results from kidney biopsies at the time of diagnosis were the best predictors of kidney failure risk in people with ANCA-associated vasculitis (AAV) with severe kidney disease, a study found. Blood creatinine levels, a marker of kidney damage, and kidney biopsy findings also predicted…

Women and younger people with ANCA-associated vasculitis (AAV) tended to report worse health-related quality of life measures than do others in assessments, according to a review of published studies. More research is needed to assess disease-specific complaints about quality of life, the investigators said — and the team also…

Tapering immunosuppressive corticosteroids as much as possible during the first year of treatment for ANCA-associated vasculitis (AAV) reduced long-term complications associated with the disorder, an analysis in Japan finds. Recent developments in AAV treatments have led to faster disease remission and fewer relapses in Asian patients, allowing for…

People newly diagnosed with microscopic polyangiitis (MPA) — a type of ANCA-associated vasculitis (AAV) — already considered to be more severe by two established measures are a higher risk of death, a study of patient registry data from Japan reports. The severity of MPA, one of the three main…

About one-quarter of adults with ANCA-associated vasculitis (AAV) in which their lungs are affected have small airway disease (SAD), which targets the tiny airways in the lungs, according to a study in China. Younger age, the presence of clumps of inflammatory cells called granulomas in the lungs, and other…

In rare cases, ANCA-associated vasculitis (AAV) can result in muscle weakness that affects mainly the trunk and the muscles closest to the trunk due to blood vessel inflammation within the muscles, a study shows. Comprehensive tests of four AAV patients with this distinct clinical feature show that muscle symptoms…

Nearly all ANCA-associated vasculitis (AAV) patients undergoing a bronchoscopy — a minimally invasive procedure to examine the lungs and air passages — at disease onset show lung involvement, a study reported. Bleeding from the alveoli, the tiny air sacs in the lungs where gases are exchanged, also was the most…

The ANCA Renal Risk Score (ARRS) — based on kidney biopsy and lab results — could accurately predict kidney failure in a large group of Scottish people with ANCA-associated vasculitis (AAV), a study shows. The test better discriminates the risk of kidney failure in AAV and may offer clinicians…

Two years of treatment with Nucala (mepolizumab) safely and effectively reduces signs and symptoms of hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis. That’s according to a real-world study in Italy that also found similar outcomes with benralizumab, a therapy that works similarly to…